0001387131-20-001050.txt : 20200205
0001387131-20-001050.hdr.sgml : 20200205
20200205180708
ACCESSION NUMBER: 0001387131-20-001050
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200203
FILED AS OF DATE: 20200205
DATE AS OF CHANGE: 20200205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Krassan Mitchell
CENTRAL INDEX KEY: 0001532232
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-00100
FILM NUMBER: 20580182
MAIL ADDRESS:
STREET 1: 951 BROKEN SOUND PARKWAY NW
STREET 2: SUITE 320
CITY: BOCA RATON
STATE: FL
ZIP: 33487
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TherapeuticsMD, Inc.
CENTRAL INDEX KEY: 0000025743
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 870233535
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 951 YAMATO ROAD, SUITE 220
CITY: BOCA RATON
STATE: FL
ZIP: 33431
BUSINESS PHONE: 561-961-1900
MAIL ADDRESS:
STREET 1: 951 YAMATO ROAD, SUITE 220
CITY: BOCA RATON
STATE: FL
ZIP: 33431
FORMER COMPANY:
FORMER CONFORMED NAME: AMHN, Inc.
DATE OF NAME CHANGE: 20090930
FORMER COMPANY:
FORMER CONFORMED NAME: CROFF ENTERPRISES INC
DATE OF NAME CHANGE: 19970915
FORMER COMPANY:
FORMER CONFORMED NAME: CROFF OIL CO
DATE OF NAME CHANGE: 19920703
4
1
krassan-form4_020320.xml
OWNERSHIP DOCUMENT
X0306
4
2020-02-03
0
0000025743
TherapeuticsMD, Inc.
TXMD
0001532232
Krassan Mitchell
951 YAMATO ROAD, SUITE 220
BOCA RATON
FL
33431
0
1
0
0
Chief Strategy Officer
Common Stock
2020-02-03
4
M
0
105703
0.1874
A
105703
D
Common Stock
2020-02-03
4
M
0
194297
0.2037
A
300000
D
Common Stock
2020-02-03
4
S
0
300000
2.2564
D
0
D
Non-Qualified Stock Option (right to buy)
0.1874
2020-02-03
4
M
0
105703
0
D
2011-05-01
2020-05-01
Common Stock
105703
0
D
Non-Qualified Stock Option (right to buy)
0.2037
2020-02-03
4
M
0
194297
0
D
2013-09-01
2020-09-01
Common Stock
194297
489658
D
The sales were made pursuant to the Reporting Person's 10b5-1 trading plan dated December 10, 2019 with respect to shares of common stock underlying options to purchase common stock that expire on or before September 2020.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.285, inclusive. The reporting person undertakes to provide TherapeuticsMD, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Mitchell Krassan
2020-02-05